Webinar
Progress in applying human iPSC-derived cells to drug discovery
In this webinar, four industry experts present data on bit.bio’s deterministically programmed human iPSC-derived ioCells used across key drug discovery stages.
In this webinar, four industry experts present data on bit.bio’s deterministically programmed human iPSC-derived ioCells used across key drug discovery stages.
In drug discovery, researchers need reliable, ready-to-use human cell models that deliver reproducible results at every stage of the workflow. Join four industry experts as they present data on bit.bio’s deterministically programmed human iPSC-derived ioCells used across key drug discovery stages. Through case studies and real-world applications, you will learn how these cells and the associated protocols support workflows in target identification, assay development, disease modelling, and toxicology.
Key learning points:
- Discover quick and easy generation of gene knockouts and CRISPR screens for target ID and validation in human iPSC-derived neurons and microglia using CRISPR-Ready ioCells
- Learn about assay development in neuroinflammation and demyelinating diseases using neuronal and glial co-cultures
Explore disease modelling in excitatory neurons with ALS-associated phenotypes using high-throughput MEA - See data for predicting drug-induced liver injury in toxicology studies with new human iPSC-derived liver models